Aldeyra Therapeutics Stock News

Aldeyra Therapeutics' (ALDX) CEO Todd Brady on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AbbVie's Rinvoq Gets Label Expansion To Treat Ulcerative Colitis AbbVie, Inc. (NYSE: ABBV) announced 

Aldeyra Therapeutics press release (ALDX): FY GAAP EPS of -$1.07 beats by $0.02.Cash and Cash Equivalents of $229.8 Million as of December 31, 2021; Projected Cash Runway Through 2023

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today reported recent corporate highlights and financial results for the year ended December 31, 2021. “In addition to our planned completion of clinical development for reproxalap in dry eye disease, 2022 is expected to highlight data milestones for our systemic and retinal disease platform

Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ: TGA ) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ: IKNA ) is projected to report earnings for its fourth quarter. • RF Industries (NASDAQ: RFIL ) is likely to report quarterly earnings at $0.04 per share on revenue of $15.84 million. • Destination XL Group (NASDAQ: DXLG ) is estimated to report quarterly earnings at $0.13 per share on revenue of $131.88 million. • Liquidia (NASDAQ: LQDA ) is projected to report quarterly loss at $0.11 per share on revenue of $3.05 million. • IMV (NASDAQ: IMV ) is projected to report quarterly loss at $0.13 per share on revenue of $50.00 thousand. • Redhill Biopharma (NASDAQ: RDHL ) is likely to report quarterly loss at $0.33 per share on revenue of $24.08 million. • Designer Brands (NYSE: DBI ) is likely to report quarterly earnings at $0.16 per share on revenue of $839.61 million. • Kirkland''s (NASDAQ: KIRK ) is expected to report quarterly earnings at $0.

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, March 17, 2022 to report financial results for the year ended December 31, 2021 and discuss recent corporate highlights. The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 132077. A live webcast of the conference call will also be available on the Investors & Media page of the Al

Aldeyra Therapeutics (ALDX) began a Phase 2 trial of its drug candidate, ADX-2191, for the treatment of a rare eye disorder called retinitis pigmentosa. Retinitis Pigmentosa, which…

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that it has initiated a Phase 2 clinical trial of ADX-2191 (intravitreal methotrexate 0.8%), an investigational new drug product, for the treatment of retinitis pigmentosa (RP). RP is a clinical group of rare genetic eye diseases characterized by retinal cell death and loss o

Related Stocks: ALDX , OSK , AG , ABEO , SNGX , VMW , XCUR , SVM , FSM ,

Aldeyra Therapeutics is currently undervalued with near-term catalysts, in my view.

Aldeyra Therapeutics (ALDX) announces positive top-line data from a Phase 2 clinical trial comparing ocular discomfort and itching symptom scores of reproxalap ophthalmic solution

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated dis

Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from the same is expected in the second half of 2022.